Severe periocular bleeding induced by bevacizumab in a patient with recurrent glioblastoma multiforme

Eryilmaz M. K., Mutlu H., Musri F. Y., Salim D. K., Tazegul G., COŞKUN H. Ş.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.23, no.5, pp.392-395, 2017 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 23 Issue: 5
  • Publication Date: 2017
  • Doi Number: 10.1177/1078155216643858
  • Journal Name: JOURNAL OF ONCOLOGY PHARMACY PRACTICE
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.392-395
  • Keywords: Bevacizumab, bleeding, recurrent glioblastome multiforme, COMPLICATIONS, TEMOZOLOMIDE, THERAPY, GLIOMAS
  • Akdeniz University Affiliated: Yes

Abstract

Bevacizumab is a humanized monoclonal antibody targeting vascular endothelial growth factor, and it has been shown to improve progression-free survival in patients with recurrent glioblastome multiforme when administered as second-line therapy. However, it has been associated with serious and fatal hemorrhagic events. Here, we present a 68-year-old male who developed severe periocular bleeding while on bevacizumab for recurrent temozolamide-resistant glioblastome multiforme.